MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-08-2022
Albireo Pharma Operating Expenses 2011-2026 | ALBO
Annual Operating Expenses Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 163 M | 105 M | 70.7 M | 50.6 M | 24.6 M | 14 M | 19.8 M | 19.3 M | 20.6 M | 19.3 M | 23.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 163 M | 14 M | 48.1 M |
Quarterly Operating Expenses Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 42.4 M | 35.5 M | 41.7 M | - | 29.2 M | 20.1 M | 31.1 M | - | 22 M | 16.5 M | 15.9 M | - | 12.9 M | 11.1 M | 11.8 M | - | 6.53 M | 6.61 M | 6.1 M | - | 3.47 M | 6.03 M | 2.75 M | 3.23 M | 16.3 M | 6.58 M | 4.53 M | 5.24 M | 15.6 M | 4.75 M | 5.24 M | 5.04 M | 16.2 M | 5.22 M | 5.04 M | 5.91 M | 13.6 M | 4.73 M | 5.91 M | 4.37 M | 18.6 M | 5.32 M | 4.37 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 42.4 M | 2.75 M | 12.6 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Heron Therapeutics
HRTX
|
281 M | $ 0.79 | 1.9 % | $ 132 M |  USA |
 |
Altimmune
ALT
|
94.5 M | $ 3.44 | 2.99 % | $ 303 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 218.03 | -1.74 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Aileron Therapeutics
ALRN
|
65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Incyte Corporation
INCY
|
1.62 B | $ 90.43 | -0.21 % | $ 17.7 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Inovio Pharmaceuticals
INO
|
145 M | $ 1.54 | -2.41 % | $ 34.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
242 M | $ 13.57 | 7.1 % | $ 818 M | USA |
 |
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Inventiva S.A.
IVA
|
36.2 M | $ 6.07 | 4.97 % | $ 138 M | France |
 |
Calithera Biosciences
CALA
|
125 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
142 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | USA |
 |
KalVista Pharmaceuticals
KALV
|
188 M | $ 16.82 | -1.06 % | $ 835 M | Britain |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
425 M | - | -7.23 % | $ 13 M | USA |
 |
Kamada Ltd.
KMDA
|
69 K | $ 8.27 | 0.24 % | $ 260 M | Israel |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
40.4 M | $ 2.13 | 1.67 % | $ 199 M | Israel |
 |
Karyopharm Therapeutics
KPTI
|
265 M | $ 7.11 | -6.82 % | $ 866 K | USA |
 |
Denali Therapeutics
DNLI
|
502 M | $ 20.99 | 4.07 % | $ 3.45 B | USA |
 |
Keros Therapeutics
KROS
|
176 M | $ 11.16 | 1.82 % | $ 415 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
96.2 M | $ 4.35 | 2.48 % | $ 722 M | Canada |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
12 M | - | -5.98 % | $ 34.1 M | USA |